Viking Therapeutics (VKTX) Common Equity (2014 - 2026)
Viking Therapeutics (VKTX) posted Common Equity of $408.3 million for Q2 2026, down 18.65% sequentially from $501.9 million in Q1 2026, and down 48.67% YoY from $795.5 million in Q2 2025.
Viking Therapeutics (VKTX) Common Equity (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Common Equity for 13 years, with the latest figure at $408.3 million in Q2 2026.
- Quarterly Common Equity fell 48.67% year-over-year to $408.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $408.3 million (down 48.67% YoY) and the FY2025 annual result came in at $639.1 million, down 27.4% from the prior year.
- Common Equity slipped to $408.3 million in Q2 2026 per VKTX's latest filing, from $501.9 million in the prior quarter.
- Over five years, Common Equity peaked at $933.9 million in Q1 2024 and troughed at $134.1 million in Q1 2023.
- A 5-year average of $524.0 million and a median of $455.1 million in 2026 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2026: Common Equity jumped 596.6% in 2024, then plunged 48.67% in 2026.
- Over 5 years, Common Equity stood at $145.3 million in 2022, then jumped by 139.76% to $348.4 million in 2023, then jumped by 152.65% to $880.3 million in 2024, then dropped by 27.4% to $639.1 million in 2025, then slumped by 36.11% to $408.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $408.3 million, $501.9 million, and $639.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | 408.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 408.32 Mn |
| Mar 31, 2026 | 501.92 Mn |
| Dec 31, 2025 | 639.06 Mn |
| Sep 30, 2025 | 713.03 Mn |
| Jun 30, 2025 | 795.46 Mn |
| Mar 31, 2025 | 846.92 Mn |
| Dec 31, 2024 | 880.28 Mn |
| Sep 30, 2024 | 911.45 Mn |
| Jun 30, 2024 | 920.98 Mn |
| Mar 31, 2024 | 933.89 Mn |
| Dec 31, 2023 | 348.42 Mn |
| Sep 30, 2023 | 368.24 Mn |
| Jun 30, 2023 | 386.12 Mn |
| Mar 31, 2023 | 134.07 Mn |
| Dec 31, 2022 | 145.32 Mn |
| Sep 30, 2022 | 151.29 Mn |
| Jun 30, 2022 | 165.23 Mn |
| Mar 31, 2022 | 182.27 Mn |
| Dec 31, 2021 | 201.88 Mn |
| Sep 30, 2021 | 213.12 Mn |